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Abstract
Background/Aim. Recent studies have shown that bio-
logical treatments for rheumatoid arthritis can change the
course of rheumatoid arthritis and improve functional abil-
ity of patients with rheumatoid arthritis. In spite of this fact,
use of biological therapy is still limited by high prices of
these medicines, especially in countries in socioeconomic
transition. The aim of our study was to compare cost-
effectiveness of a combination of tocilizumab and metho-
trexate with methotrexate alone for rheumatoid arthritis in
Serbia, a country in socioeconomic transition. Methods.
For the purpose of our study we designed a Markov model
using data on therapy efficacy from the available literature,
and data on the costs of health states calculated from rec-
ords of actual patients treated in the Clinical Center Kra-
gujevac, Serbia. The duration of one cycle in our model was
set at one month, and the time horizon was 480 months (40
years). The study was done from the social perspective, and
all the costs and outcomes were discounted for 3% per year.
Results. Treating rheumatoid arthritis with disease-
modifying antirheumatic drugs (DMARDs) alone was more
cost-effective in comparison with a combination of biologic
treatment with tocilizumab and DMARDs. The total costs
for treating a patient with DMARDs for one year were on
average 261,945.42 RSD, or 2,497.70 Euro and the total
costs for treatment with tocilizimab plus DMARDs were on
average 1,959,217.44 RSD, or 18,659.20 Euro. However,
these results are susceptible to changes in costs and treat-
ment effects of tocilizumab in patients with more severe
forms of rheumatoid arthritis. Conclusion. Our results
show that the use of tocilizumab for rheumatoid arthrits in
economic environment of Serbia is not cost-effective. Use
of tocilizumab for treating rheumatoid arthritis can become
affordable, if costs of its use become lower. In order to start
using expensive biologic medicines in patients in transitional
countries, special strategy and pricing policy of international
pharmaceutical companies are necessary, which would in-
clude calculation of prices of biologic medicines on the ba-
sis of local pharmacoeconomic studies.
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Apstrakt
Uvod/Cilj. Nedavne studije ukazale su da biološka terapija
za reumatoidni artritis može menjati tok bolesti i popraviti
funkcionalnu sposobnost obolelih. Uprkos tome, upotreba
bioloških lekova ograniÿena je visokom cenom ovih lekova,
posebno u zemljama koje su u socioekonomskoj tranziciji.
Cilj ovog istraživanja bio je da se uporede troškovi i efekat
kombinacije tocilizumaba i metotreksata sa metotreksatom
u terapiji reumatoidnog artritisa u Srbiji, zemlji u socioeko-
nomskoj tranziciji. Metode. Za potrebe ovog istraživanja
konstruisan je Markovljev model na osnovu podataka o efi-
kasnosti iz dostupne literature, dok su podaci o troškovima
za sva zdravstvena stanja procenjeni iz dostupne dokumen-
tacije obolelih od reumatoidnog artritisa koji se leÿe u Klini-
ÿkom centru Kragujevac, Srbija. Jedan ciklus u modelu tra-
jao je jedan mesec, a ukupan vremenski horizont bio je 480
meseci, odnosno 40 godina. Studija je izvedena sa aspekta
društva u celini, a svim troškovima i ishodima je pridodata
diskontna stopa od 3%. Rezultati. Leÿenje reumatoidnog
artritisa standardnom, nebiološkom terapijom je u pogledu
odnosa troškova i efekata povoljnije u poreĀenju sa biološ-
kom terapijom tocilizumabom u kombinaciji sa standar-
dnom nebiološkom terapijom. Ukupni troškovi leÿenja re-Volumen 71, Broj 2 VOJNOSANITETSKI PREGLED Strana 145
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umatoidnog artritisa standardnom nebiološkom terapijom
tokom jedne godine leÿenja po bolesniku iznose 261 945,42
dinara Republike Srbije, odnosno 2 497,70 eura, a ukupni
troškovi leÿenja tocilizumabom u kombinaciji sa standar-
dnom nebiloškom terapijom u toku jedne godine po paci-
jentu iznose 1 959 217,44 dinara Republike Srbije, odnosno
18 659,20 eura. Ipak, ovi rezultati su podložni promenama i
uticaju troškova i efekata terapije tocilizumabom kod boles-
nika sa težom formom bolesti. Zakljuÿak. Rezultati našeg
istraživanja pokazuju da primena tocilizumaba u leÿenju re-
umatoidnog artritisa nije farmakoekonomski isplativa. Pri-
mena tocilizumaba za leÿenje reumatoidnog artritisa može
postati isplativija u farmakoekonomskom smislu, ukoliko
cena tocilizumaba postane niža. Upotreba skupe biološke
terapije kod obolelih od reumatoidnog artritisa u zemljama
u socioekonomskoj tranziciji može biti izvesna jedino uz
postojanje posebne strategije i cenovne politike internacio-
nalnih farmaceutskih kompanija, što podrazumeva odreĀi-
vanje cene ovih lekova na bazi lokalnih farmakoekonomskih
studija.
Kljuÿne reÿi:
artritis, reumatoidni; farmakoekonomika; biološka
terapija; metotreksat; srbija.
Introduction
Rheumatoid arthritis is a chronic disease characterized
by systemic inflammation and continous irreversible de-
struction of joints mediated with immunological mecha-
nisms 
1. Rheumatoid arthritis affects 0.5–1% of general
population, with severe destructions of joints encountered in
15% of patients. The prevalence of rheumatoid arthritis is 3–
4 times higher in women than in men, with the tendency to
rise with aging 
2, 3. Diagnosis of rheumatoid arthritis is based
on the criteria established by the American College of
Rheumatology (ACR), and 4 of 7 criteria must be present:
morning stiffness, arthritis in 3 or more joint areas, arthritis
of hand joints (more than 1 joint), symmetrical arthritis,
rheumatoid nodules, elevated serum rheumatoid factor and
typical radiographic changes (with exception for the two last
criteria, the listed changes must persist for at least 6 weeks) 
4.
These criteria have been lately recognized as less sensitive
and updated by the European League Against Rheumatism
(EULAR) during 2010, with special concern for early arthri-
tis 
5. The Health Assessment Questionnaire (HAQ) is a
dominant instrument for capturing a state of disability in pa-
tient with rheumatoid arthritis. The HAQ estimates func-
tional status of patients in several domains: disability, pain
and discomfort, adverse drug reactions and economic issues
of treating rheumatoid arthritis. Nowdays, HAQ is the most
widely used techinque for evaluating disability in patients
with rheumatoid arthritis 
6.
The therapeutic approach in rheumatoid arthritis in-
volves two strategies: to prevent the spread of chronic in-
flammatory process and to ensure protection of affected
joints from further deterioration 
7. Treatment of rheumatoid
artritis with standard disease modifying anti-rheumatic drugɾ
(DMARDs), and newer biologic therapy, alone or in combi-
nation, has proven efficacy. Among DMARDs, methotrex-
ate, sulphasalasine and leflunomide with their immunosu-
pressant actions have shown the greatest impact on the
course of rheumatoid arthritis 
8. Methotrexate is considered
to be the gold standard for treatment of rheumatoid arthritis
because of its good efficacy and moderate adverse reactions.
However, the response to methotrexate is sometimes inade-
quate or unsatisfying, so biologic medicines remain the only
solution 
7. The targets of biologic medicines are different
cytokines or their receptors, and these medicines (etanercept,
adalimumab, infliximab, tocilizumab, rituximab and others)
have shown beneficial effect on the course of rheumatoid
arthritis 
7, 9, 10. Biologic therapy use differs among Europian
countries and depends mostly on available budgets for buy-
ing these medicines. High prices of biologic medicines are
the main reason for restrictive utilization of these medi-
cines 
11. The majority of European countries uses similar
criteria for reimbursing prescription of a biologic medicine
like those recommended by the National Institute for Clinical
Excellence (NICE) from U.K.: treatment with biologic medi-
cine (mostly with a TNF blocker) is given to a patient whose
response to methotrexate is poor and incomplete; if there is
no response to the first biologic medicine after 3 to 6 months
of treatment, the patient should be switched to another bio-
logic medicine 
12–14.
In spite of large evidence on therapeutic effects of bio-
logic medicines on rheumatoid arthritis, the data is limited to
economic aspects of this therapy, especially with newer bio-
logic medicines. The question of cost-effectiveness ratio is
important issue nowadays, especially in countries in socio-
economic transition, since introduction of new medicines
often means a substantial increase in total health care costs.
Economic burden of rheumatoid arthritis involves direct and
indirect costs, and it depends mostly on prices of a pre-
scribed medication 
11.
The aim of this study was to compare cost-effectiveness
of two therapeutic strategies in patients with rheumatoid ar-
thritis: treatment with DMARDs alone or in combination
with tocilizumab using a Markov model based on data on ef-
ficacy from published clinical trials and costs sampled from
the economic environment in Serbia.
Methods
The Markov model was designed in order to compare
the cost-effectiveness of two therapeutic strategies for pa-
tients with rheumatoid arthritis. The startegies were therapy
with DMARDs alone and therapy with a combination of
DMARDs and tocilizumab. For the purpose of modelling we
presented rheumatoid arthritis as 5 primary health states
based on the Health Assesment Questionnaire (HAQ), ac-
cording to Kobelt et al. 
15. These states reflect chronic course
and severity of rheumatoid arthritis: HAQ score less than
0.6, HAQ score from 0.6 to 1.1, HAQ score from 1.1 to 1.6,Strana 146 VOJNOSANITETSKI PREGLED Volumen 71, Broj 2
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HAQ score from 1.6 to 2.1 and HAQ scores higher than 2.1.
For every node we added death as potential state. After tak-
ing into account activity of the disease, each primary HAQ
state was subdivided into two new states: one with high and
another with low activity. Each state in the model except
death was not definitive, and a hypothetic patient could move
from one to another state, depending on natural course of the
disease and experiences from clinical trials. The initial pa-
tient distribution, transitional probabilities, utilities, and ef-
fectiveness of the two treatment options were obtained from
the available literature 
15–17, while the costs of health states
were calculated from records of actual patients treated in
Clinical Center Kragujevac, Serbia.
The duration of one cycle in our model was one month,
and the time horizon was 480 months (40 years). All the
costs and outcomes were analyzed from social perspective
and discounted for 3% annually. For the purpose of model-
ling, we conducted a pilot survey to estimate costs of rheu-
matoid arthritis. We analyzed all the aspects of economic is-
sues of treating rheumatoid arthritis. Using interview tech-
niques we collected data from our patients about direct (costs
of medicines, hospitalization, diagnostic procedures, medical
exams etc.) and indirect costs (costs of transportation, lost
wages etc.) of treating rheumatoid arthritis. All the costs
were expressed in 2010 Serbian dinars (RSD) and the data on
health services utilization were collected from files of rheu-
matoid arthritis patients, for each HAQ state and disease ac-
tivity score separately. The patients were randomly chosen
from the population of patients with rheumatoid arthritis
treated in the Clinical Center Kragujevac, Serbia, during one
year (from June 2009 to June 2010). The prices of health
services were obtained from the Republic Institute for Health
Insurance (RIHI) Tariff Book and prices of medicines were
those from the list of medicines financed by the RIHI, issued
in 2010 
18. The process of modelling requires a definition of
willingness to pay, i.e. how much a society is willing to pay
for one quality-adjusted life year (QALY) gained with cer-
tain treatment of the disease. For societies in socioeconomic
transition there is a recommendation from the World Bank
that the value of willingness to pay should be equal to two to
three multiples of gross national income per capita. In case
of Serbia, gross national income per capita (GDP/capita) was
563,400 dinars (RSD) in 2009 
19. We also used the value of
average monthly net income in Serbia during 2009 to calcu-
late the costs of lost wages.
The model was constructed using TreeAge pro
® soft-
ware, version 2006 
20. We performed Monte Carlo simula-
tions using microsimulation trial, where cohorts of virtual
patients, which consist of 1,000 virtual patients, passed
through all hypothetical scenarios. The model of Monte
Carlo simulation randomly chooses patients from the cohort,
and every patient from the cohort runs through different sce-
narios and results are the summaries as incremental cost-
effectiveness ratio 
21–23. For each therapeutic option we cal-
culated the mean costs and the mean effects, and expressed
them also as incremental cost-effectiveness ratio. We fol-
lowed the following outcomes: gains in utility for each ther-
apy option, expressed as QALYs gained, and total and mean
costs incurred by each therapeutic option. Incremental cost
effectiveness ratio for tocilizumab vs DMARDs therapy as
baseline was also calculated. Two-way sensitivity analysis (±
50% of baseline values of a variable) was performed in order
to check for robustness of the model results, and its outcome
is shown as a Tornado diagram.
Results
Treating rheumatoid arthritis with DMARDs alone was
more cost-effective than a combination of biologic treatment
with tocilizumab and DMARDs. The total costs for treating a
patient with DMARDs for one year (2009–2010) were on
average 261,945.42 RSD, or 2,497.70 Euro (on August 12,
2010) and total costs for treatment with tocilizimab plus
DMARDs were on average 1,959,217.44 RSD, or 18659,20
Euro (on August 12, 2010) (Figure 1).
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Fig. 1 – Total costs for one year-treatment (2009–2010) per
patient for DMDARs and a combination of tocilizumab and
metotrexate (prices on August 12, 2010).
Using the cost-effectiveness calculation method we com-
pared total costs per QALY gained for both examined thera-
peutic options. The results of this method indicate that stan-
dard non-biological therapy requires much less investment
than therapy with a combination of tocilizumab and metho-
trexate for higher gain in QALY. Treatment with standard
non-biological therapy for gain of one QALY requires invest-
ment of 1,446,640.78 RSD, which is more cost-effective than
treatment with tocilizumab and methotrexate together which
costs 6,171,321.57 RSD per QALY gained. The results of
cost-effectiveness analysis are shown in Table 1.
The distribution of incremental cost-effectiveness ratios
(ICERs) calculated by Monte Carlo simulations (using a co-
hort of 1,000 virtual patients) for total costs per QALY is
shown in Figure 2. For therapeutic option combination of to-
cilizumab and metotrexate the calculated ICERs (with only
methotrexate as baseline comparator) for the majority of
virtual patients fall on the left side of willingness-to-pay line,
which indicates that this kind of biological therapy for rheu-
matoid arthritis in Serbian socioeconomic enviroment is not
cost-effective.
In order to check robustness of our conclusion, we
made two-way sensitive analysis using a Tornado diagram.
In this analysis, all the parameters were varied simultane-
ously in the range ± 50%. The most influential variablesVolumen 71, Broj 2 VOJNOSANITETSKI PREGLED Strana 147
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were those which describe state with HAQ score higher than
2.1: the costs for non-biological therapy for HAQ states
higher than 2.1, discount rate for the costs, the costs for bio-
logical therapy for HAQ state higher than 2.1 with low ac-
tivity of the disease, utility score for HAQ state higher than
2.1 with high activity of the disease and discount rate for ef-
fects of the treatment. With changes in these variables, the
value of the net monetary benefit becomes negative, within
the range from -7.3 to -2.8 milions of Serbian dinars, which
means that our conclusion is susceptible to changes in costs
and treatment effects of tocilizumab in patients with more
severe forms of rheumatoid arthritis.
Discussion
Efficacy of tocilizumab has already been tested in a re-
cent randomized controlled clinical trial, and because it
achieved a significant benefit on the course of rheumatoid
arthritis, it was approved for treatment of rheumatoid arthrits
in Europian Union 
24, 25. Nevertheless, pharmacoeconomic
studies on tocilizumab in rheumatoid arthritis have not been
conducted to this date, and certainly not based on socioeco-
nomic enviroment of Balkan countries in transition from
controlled economy to free market.
The use of biological therapy for rheumatoid arthritis is
not common within the Serbian health system, and is limited
mostly by high prices of these medications and restrictive
treatment guidelines. Similiar experience has been gained by
physicians and patients in most countries of Balkan region 
11.
The results of our model suggest that therapy with a
combination of tocilizumab and methotrexate in comparison
with methotrexate alone is not cost-effective. A gain in
QALYs is lower and costs are higher with tocilizumab and
methotrexate together than with methotrexate alone. Apart
from relatively moderate clinical effect of tocilizumab, an
important reason for such an outcome was a large dispropor-
tion between prices of medicines, which are almost the same
in Serbia and in developed European countries, and prices of
health care services, which are 10–100 times lower in Serbia
than in developed countries. Therefore, beneficial effects of
tocilizumab on decrease in health care utilization do not
translate to significant savings in costs. The prices of health
care services in Serbia are controlled by the RIHI, which
publishes them periodically in its internal publications,
which are not accessible to general public. To show how un-
realistic these prices are, we mention the prices of one hos-
pital day for basic care, which range from 10 to 20 euro, de-
pending on the branch of medicine. Actually, we have two
systems operating in the same time: free market rules for
medicines, and controlled economy rules for health care
services. Such duality inevitably creates paradoxical results
of health economics studies situated in Balkan countries in
socioeconomic transition.
The sensitivity analysis shows that this conclusion
could be changed if the effectiveness of tocilizumab is in-
creased in more severe forms of rheumatoid arthritis (which
is unlikely to happen, since the degree of efficacy was well-
established) or if the price of tocilizumab goes down and the
prices of health care services go up. The second option (de-
crease in the price of medicine) could happen if the producer
of tocilizumab finds interest to increase the volume of its
sales in transitional and other poor countries and maintain
profit selling more of the less expensive medicine. For the
time being, this is also the only option how patients with se-
vere forms of rheumatoid arthritis in transitional Balkan
countries could reach this effective but very expensive medi-
cine.
In order to start using expensive biologic medicines in
patients in transitional countries, special strategy and pricing
policies of international pharmaceutical companies are nec-
essary. The prices of biologic medicines should be calculated
on the basis of local pharmacoeconomic studies (like this
Table 1
Cost effectiveness analysis of the two therapeutic strategies: disease modifying anti-rheumatic drugɾ (DMARDs)
only and tocilizumab in combination with methotrexate
Therapeutic
option Costs (RSD)
The
difference in
costs
(RSD)
Effectiveness
expressed in
quality ad-
justed life
years
(QALY)
The difference
in effectiveness
(QALY)
Cost-effectiveness
ratio
( RSD/QALY)
Incremental
cost
effectiveness
ratio (ICER)
DMDARs 7.788.768,97 5.38 1.446.640,78
Tocilizumab +
methotrexate 20.731.954,15 12.943.185,18 3.36 -2.02 6.171.321,38 (Dominated)
Incremental cost effectiveness Tocilizumab + methotrexate
vs disease modifying drug therapy
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Fig. 2 – Distributions of the incremental cost-effectiveness
ratio (ICER) calculated by Monte Carlo simulation for the
total costs per quality-adjusted life years (QALY) for
tocilizumab and metotrexate comparing with the standard
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one), up to the point where the prices make the studies out-
comes cost-effective. This would provide for the acceptance of
such medicines by the local health insurance funds and suffi-
cient financing to make registration of the medicine in such a
country profitable for the pharmaceutical companies 
26.
Conclusion
Due to the progressive nature and chronic course of
rheumatoid arthritis, it is important to estimate cost-
effectiveness of new medicines for rheumatoid arthritis by
pharmacoeconomic modelling. Cost-effectiveness ratio of
tocilizumab could be acceptable if the price of tocilizumab
reaches a lower value. Further research is necessary to in-
dentify a subset of patients with rheumatoid arthritis in
which tocilizumab could be cost-effective therapy.
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